Royal Bank of Canada Acquires 3,961 Shares of Medpace Holdings, Inc. $MEDP

Royal Bank of Canada raised its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 3.3% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 123,929 shares of the company’s stock after buying an additional 3,961 shares during the quarter. Royal Bank of Canada’s holdings in Medpace were worth $59,510,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Steigerwald Gordon & Koch Inc. acquired a new stake in shares of Medpace during the 4th quarter worth approximately $30,000. Elyxium Wealth LLC acquired a new position in shares of Medpace during the 4th quarter valued at $30,000. Quarry LP bought a new position in Medpace during the third quarter worth $35,000. Bayban bought a new position in Medpace during the fourth quarter worth $44,000. Finally, Core Wealth Advisors LLC acquired a new stake in Medpace in the fourth quarter worth $47,000. 77.98% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on MEDP. Mizuho lifted their price target on shares of Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. Leerink Partners set a $620.00 price objective on shares of Medpace in a research report on Thursday, July 23rd. Royal Bank Of Canada raised their target price on Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. Jefferies Financial Group lowered Medpace from a “buy” rating to a “hold” rating and boosted their target price for the company from $490.00 to $515.00 in a research report on Tuesday, July 7th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $535.00 price target on shares of Medpace in a research note on Thursday, July 23rd. Two investment analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $584.18.

Medpace Trading Down 0.2%

Shares of MEDP stock opened at $577.11 on Friday. The firm has a fifty day simple moving average of $507.61 and a two-hundred day simple moving average of $493.77. Medpace Holdings, Inc. has a 12 month low of $373.00 and a 12 month high of $677.90. The firm has a market capitalization of $16.11 billion, a PE ratio of 33.83, a price-to-earnings-growth ratio of 2.57 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. The firm had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business’s quarterly revenue was up 17.2% compared to the same quarter last year. During the same period last year, the firm earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO August J. Troendle sold 3,510 shares of the company’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $600.01, for a total value of $2,106,035.10. Following the sale, the chief executive officer owned 638,946 shares in the company, valued at $383,373,989.46. This represents a 0.55% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Susan E. Burwig sold 7,500 shares of the firm’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $600.00, for a total transaction of $4,500,000.00. Following the completion of the transaction, the vice president directly owned 62,984 shares in the company, valued at approximately $37,790,400. The trade was a 10.64% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 31,087 shares of company stock worth $16,203,054 in the last quarter. Insiders own 20.50% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.